U.S. Markets close in 5 mins
  • S&P 500

    3,903.44
    -20.24 (-0.52%)
     
  • Dow 30

    31,272.97
    -217.10 (-0.69%)
     
  • Nasdaq

    11,391.12
    -27.04 (-0.24%)
     
  • Russell 2000

    1,779.78
    +4.93 (+0.28%)
     
  • Crude Oil

    111.64
    +2.05 (+1.87%)
     
  • Gold

    1,840.90
    +25.00 (+1.38%)
     
  • Silver

    21.87
    +0.34 (+1.57%)
     
  • EUR/USD

    1.0592
    +0.0126 (+1.2075%)
     
  • 10-Yr Bond

    2.8550
    -0.0310 (-1.07%)
     
  • Vix

    29.73
    -1.23 (-3.97%)
     
  • GBP/USD

    1.2492
    +0.0150 (+1.2130%)
     
  • USD/JPY

    127.6990
    -0.5980 (-0.4661%)
     
  • BTC-USD

    29,987.27
    +682.71 (+2.33%)
     
  • CMC Crypto 200

    666.84
    +14.61 (+2.24%)
     
  • FTSE 100

    7,302.74
    -135.35 (-1.82%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Imara Inc (NASDAQ: IMRA) has announced data from a pre-specified interim analysis from its Forte Phase 2b trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia.

  • Subjects in the Forte trial were randomized to either a lower dose group (200 mg or 300 mg), higher-dose group (300 mg or 400 mg), or placebo.

  • The median baseline transfusion burden in each higher dose tovinontrine and placebo group was 7.5 red blood cell (RBC) units/12 weeks.

  • Interim data from the Forte study demonstrated tovinontrine was well-tolerated, with the most frequent adverse being nausea, headache, and dizziness.

  • Four (9.3%) subjects discontinued due to adverse events considered related to the study drug.

  • The proportion of subjects who had over 33% reduction in transfusion burden (of at least two units) was greater in the higher dose tovinontrine group (7/8) versus placebo, despite an unexpectedly high response rate in the placebo group (8/12).

  • Lower dose tovinontrine did not show a higher response rate when compared to the placebo group. No substantial differences between groups were observed in the transfusion burden response rate.

  • Additional data will be presented as part of a key efficacy analysis expected in Q1 of 2022.

  • Price Action: IMRA shares are up 1.11% at $3.63 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.